Yuqing (Philip) Ruan

Experience: Joint Venture and Technology Collaboration: Assisted BP in creation of multiple joint ventures in China; Assisted Castrol in collaborations with auto makers and service providers in China; Assisted in a cross-border technology transfer transaction for multiple China-based pharmaceutical company as licensee; Assisted several US companies in managing its IP portfolio and IP enforcement in China; M&A: Advised Tuscan Holding Corp in its de-SPAC transaction with Microvast; Advised SJL Partners, KCC and Wonik in connection with the matters relating to their US$3.1 billion acquisition of MPM Holdings (Momentive), a leading global specialty chemicals and materials company based in Waterford, NY, handling post-closing corporate restructuring and business integration (including in mainland China, Taiwan, Japan and Singapore); Advised on post-closing corporate restructuring (including in Japan, mainland China, Hong Kong) for Quaker Houghton, a global supplier of industrial process fluids; Represented Medtronic is divesting its subsidiary Beijing Libeier Bio-engineering Institute, Ltd. to AK Medical International Limited, a HK listed company at the price of US$ 40.2 million; Advised Volvo CE in its divestiture of NHL; Assisted a US investor in acquisition of another US company's agrichemical business, and associated asset transfer in China; Assisted Volvo CE in acquisition of Terex, a UK-based company's off-road hauler business, conducting due diligence on the target's Chinese business and assisted in CSRC filing; VC Investment: Advised a RMB fund on its USD10 million preferred stock investment in a US startup specialized in the reagents and services of next generation sequencing; Advised a USD fund on its RMB90 million preferred stock investment in a China-based manufacturer of orthopedics products; Advised a USD fund on its USD15 million preferred stock investment in a China-based provider of pharmacy benefit manager services; Advised a RMB fund on its USD10 million preferred stock investment in a China-based intraocular lens manufacturer; Assisted a USD fund in its USD25 million preferred stock investment in a China-based traditional Chinese medicine service provider; Advised a Chinese fund on a 6 million preferred stock investment in a medical device manufacturer in China; Advised a US fund on a 90 million RMB preferred stock investment in a hospital management company in China; Advised a US fund on a 20 million USD preferred stock investment in a vaccine producer in China; Advised a Korean fund on a 5 million USD convertible bond investment in a chain hotel company in China